EGFR and neuroblastoma: Thus, our data may have translational application for the personalization of therapy for neuroblastomas in patients stratified for the expression of N-MYC, EGFR and CTSD. These patients could in fact benefit from a therapy combining an inhibitor of the EGFR signal with a drug inducing the expression and/or stimulating the activity of CD, such as, for instance, the nutraceutical resveratrol [29].